MEDP Medpace Holdings, Inc. - Common Stock

NAS · US · Healthcare · Diagnostics & Research · medpace.com

606.26USD+1.13%Mkt Cap: 16.73B $P/E: 35.18Today

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting…

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc Common Stock

$242.11BUSDP/E 35.5

DHR

Danaher Corporation Common Stock

$150.48BUSDP/E 38.2

NTRA

Natera, Inc. - Common Stock

Agilent Technologies, Inc. Common Stock

$47.30BUSDP/E 33.1

IQV

IQVIA Holdings, Inc. Common Stock

$42.50BUSDP/E 32.2

WAT

Waters Corporation Common Stock

$41.75BUSDP/E 107.4

ILMN

Illumina, Inc. - Common Stock

$41.23BUSDP/E 50.8

IDXX

IDEXX Laboratories, Inc. - Common Stock

$40.89BUSDP/E 36.4

MTD

Mettler-Toledo International, Inc. Common Stock

$29.78BUSDP/E 34.0

DGX

Quest Diagnostics Incorporated Common Stock

$25.75BUSDP/E 25.0

Labcorp Holdings Inc. Common Stock

$25.02BUSDP/E 25.5

Guardant Health, Inc. - Common Stock

$23.86BUSD

RVTY

Revvity, Inc. Common Stock

$16.91BUSDP/E 72.5

ERF

Eurofins Scientific SE

$14.05BUSDP/E 26.2

CRL

Charles River Laboratories International, Inc. Common Stock

$13.85BUSD

ICLR

ICON plc - Ordinary Shares

Qiagen N.V. Common Shares

$9.24BUSDP/E 22.7

GRAL

GRAIL, Inc. - Common Stock

$6.40BUSD

Key Statistics

Company

Market Cap16.73B USD

Enterprise Value16.37B USD

Revenue (TTM)2.78B USD

Gross Profit760.62M USD

Net Income (TTM)451.12M USD

Revenue/Share98.47 USD

Last Price606.26 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees6.5K

CountryUS

SectorHealthcare

IndustryDiagnostics & Research

ISIN—

Valuation

P/E (Trailing)35.18

P/E (Forward)31.04

PEG2.85

EV/EBITDA26.79

EV/Revenue5.88

P/S6.01

P/B38.56

EPS (TTM)17.03

EPS (Forward)19.31

52W Range

373.0077% of range677.90

52W High677.90 USD

52W Low373.00 USD

Profitability

Gross Margin30.06%

Oper. Margin20.76%

EBITDA Margin21.97%

Profit Margin17.83%

ROE98.27%

ROA22.84%

Growth

Revenue Growth17.20%

Earnings Growth37.10%

Cash Flow & Leverage

Operating CF713.22M USD

CapEx (TTM)31.36M USD

FCF Margin18.34%

FCF Yield3.05%

Net Debt-358.58M USD

Net Debt/EBITDA-0.59

Balance Sheet

Debt/Equity0.25

Current Ratio0.73

Quick Ratio0.66

Book Value/Sh15.54 USD

Cash/Share18.01 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating2.9 (Hold)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)589.92 USD

Upside (mean)-2.7%

Target Range370.00 USD – 692.00 USD

370.00-2.7% to mean692.00

# Analysts13

Ownership

Shares Out.27.91M

Float22.66M

Insiders18.91%

Institutions91.19%

Short Interest

Short Ratio8.4d

Short % Float7.53%

Short % Out.6.04%

Shares Short1.69M

Short (prev mo.)1.58M

Technical

SMA 50600.14 (+1.0%)

SMA 200523.81 (+15.7%)

Beta1.15

S&P 52W Chg14.58%

Avg Vol (30d)222.11K

Avg Vol (10d)263.79K

Technical Indicators

RSI (14)48.1

MACD6.6210

MACD Signal9.1938

MACD Hist.-2.5727

BB Upper637.34 USD

BB Middle606.23 USD

BB Lower575.12 USD

BB Width10.26%

ATR (14)17.24 USD

Vol Ratio (20d)1.31x